Is BTSG a Buy as Rapid Growth Collides With Its Premium Valuation?

BrightSpring’s Growth Case Is Hard to Ignore

Second-quarter revenues rose 23% year over year to $3.87 billion, while adjusted earnings per share (EPS) reached 45 cents, up 104.5%. The quarter beat the Zacks Consensus Estimate on both earnings and revenues, and BrightSpring raised its full-year outlook.

The gains were broad-based. Specialty and Infusion revenues increased 30.1%, specialty scripts rose 31%, acute infusion volume advanced more than 20%, and Provider Services revenues climbed 30.3% as home health census, de novos and acquired branches added scale. Option Care Health, Inc. OPCH, a large home and alternate-site infusion provider, offers a useful sector comparison for investors tracking demand in this care setting.

BTSG’s Premium Multiple Raises the Bar

BTSG trades at 30.7X forward 12-month earnings, well above the Zacks sub-industry average of 16.2X. That gap means investors are already paying for sustained estimate growth, successful integration and continued margin expansion.

A premium can hold when earnings keep compounding faster than expected. Yet any slowdown in script growth, admissions or operating leverage could prompt multiple compression even if the company remains profitable.

BrightSpring Has Several Paths to Margin Gains

Gross margin expanded 80 basis points year over year to 12.7%, while operating margin improved 180 basis points. Adjusted EBITDA rose 44.2%, much faster than revenue growth.

Image Source: Zacks Investment Research

Purchasing efficiencies, automation, technology standardization and a more favorable business mix can support further conversion. Management expects adjusted EBITDA to continue outpacing revenues as scale builds. The Pennant Group, Inc. PNTG, which operates home health and hospice businesses, provides another relevant reference point for investors evaluating growth and margin execution in home-based care.

Execution Risks Could Keep BTSG Volatile

Home and Community Pharmacy absorbed an estimated $50 million IRA reimbursement impact in the second quarter. Management expects about $45 million of additional impact in each remaining quarter of 2026, while customer exits continue to weigh on reported revenues.

BrightSpring is also integrating acquired branches while funding de novos, infusion expansion, automation and artificial intelligence projects. Delayed productivity gains, weaker admissions or slower technology conversion could reduce the expected spread between revenue and adjusted EBITDA growth.

Image Source: Zacks Investment Research

BTSG’s Balance Sheet Supports Reinvestment

Management expects approximately $600 million of operating cash flow in 2026 and year-end leverage below 2X before acquisitions. That financial flexibility supports expansion, debt reduction and selective tuck-in deals.

The opportunity is meaningful, but capital discipline matters. Reinvestment should favor projects with visible returns because the stock’s valuation leaves less tolerance for spending that does not translate into timely earnings growth.

BTSG’s Signals Favor Patience Over Chasing

BTSG currently sports a Zacks Rank #1 (Strong Buy). It also has a Growth Score of A, Momentum Score of A and VGM Score of A, while its Value Score is B. You can see the complete list of today’s Zacks #1 Rank stocks here.

Those signals support the near-term earnings outlook and indicate favorable growth and momentum characteristics. Still, the stock’s premium multiple and the company’s Neutral long-term stance argue for a measured decision. The business case is improving, but investors may prefer to wait for a better entry point rather than chase the shares after rapid gains.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research